Table 4.
Clinically detected (n = 22) | Screen-detected (n = 92) | P-value | Interval cancers (n = 11) | Screen-detected (n = 64) | P-value | |
---|---|---|---|---|---|---|
All Women | Regular Screeners | |||||
Regularity of screening | 0.13 | NA | ||||
Regular | 11 (50%) | 64 (70%) | 11 (100%) | 64 (100%) | ||
Irregular/no prior screening | 11 (50%) | 28 (30%) | 0 (0%) | 0 (0%) | ||
Type of screening | < .01 | 0.02 | ||||
Alternating q6 month mammo/MRI | 4 (18%) | 33 (36%) | 3 (27%) | 31 (48%) | ||
Synchronous mammo/MRI | 4 (18%) | 38 (41%) | 2 (18%) | 25 (39%) | ||
Mammo only | 13 (59%) | 18 (20%) | 5 (46%) | 7 (11%) | ||
MRI only | 1 (5%) | 3 (3%) | 1 (9%) | 1 (2%) | ||
Mammogram BIRADS density* | 0.67 | 0.45 | ||||
Predominantly fatty | 1 (5%) | 2 (2%) | 1 (10%) | 2 (3%) | ||
Scattered fibroglandular | 5 (24%) | 29 (33%) | 3 (30%) | 23 (37%) | ||
Heterogeneously dense | 9 (43%) | 43 (48%) | 4 (40%) | 33 (52%) | ||
Extremely dense | 4 (19%) | 14 (16%) | 1 (10%) | 4 (6%) | ||
Unknown | 2 (10%) | 1 (1%) | 1 (10%) | 1 (2%) | ||
MRI background parenchymal enhancement** | 0.7 | 1 | ||||
Minimal | 3 (33%) | 21 (28%) | 2 (33%) | 17 (30%) | ||
Mild | 2 (22%) | 31 (42%) | 2 (33%) | 25 (44%) | ||
Moderate | 2 (22%) | 18 (24%) | 1 (17%) | 12 (21%) | ||
NA | 2 (22%) | 4 (5%) | 1 (17%) | 3 (5%) |
Among women who had a mammogram
Among women who had an MRI